Rani Therapeutics Holdings (RANI) Preferred Stock Liabilities (2020 - 2021)
Rani Therapeutics Holdings (RANI) posted quarterly Preferred Stock Liabilities of $191.0 million for Q2 2021, up 65.39% year-over-year from $115.5 million in Q2 2020, and little changed quarter-over-quarter from $191.0 million in Q1 2021.
Rani Therapeutics Holdings (RANI) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Rani Therapeutics Holdings' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $191.0 million for Q2 2021.
- In Q2 2021, Preferred Stock Liabilities rose 65.39% year-over-year to $191.0 million; the TTM figure through Jun 2021 stood at $191.0 million (up 65.39% YoY), while the FY2020 annual figure was $184.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2021 stood at $191.0 million, roughly flat from $191.0 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $191.0 million in Q1 2021, with the low at $115.5 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 191.03 Mn |
| Mar 31, 2021 | 191.03 Mn |
| Dec 31, 2020 | 184.71 Mn |
| Sep 30, 2020 | 115.51 Mn |
| Jun 30, 2020 | 115.51 Mn |